CE Mark And Global Expansion Will Elevate HIFU Adoption

Published
08 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$5.75
76.5% undervalued intrinsic discount
15 Aug
US$1.35
Loading
1Y
-66.7%
7D
-0.7%

Author's Valuation

US$5.8

76.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 29%

Shared on24 Apr 25
Fair value Decreased 0.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 42%

AnalystConsensusTarget has increased revenue growth from 6.0% to 8.2%, increased future PE multiple from 23.9x to 34.4x and increased shares outstanding growth rate from 0.0% to 0.0%.